Shaolong Zhu

Shaolong Zhu

Auto-generated profile, based on publicly available information

Shaolong Zhu

Analytical Sciences, Sanofi Vaccines Canada Ltd, 1755 Steeles Avenue West, Toronto, ON M2R 3T4, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2021 in Biotechnology Journal
Verified
Journal Article
Closed access
PDF file
SZShaolong Zhu
Shaolong Zhu
PLPeter Liuni
Peter Liuni
TCTricia Chen
Tricia Chen
CHCamille Houy
Camille Houy
DWDerek Wilson
Derek Wilson
DJD. Andrew James
D. Andrew James

18 December 2018 in Biochemistry
Verified
Journal Article
Closed access
SZShaolong Zhu
Shaolong Zhu
PLPeter Liuni
Peter Liuni
LELuciano Ettorre
Luciano Ettorre
TCTricia Chen
Tricia Chen
JSJason Szeto
Jason Szeto
DWDerek Wilson
Derek Wilson

20 April 2026 in The Analyst
Verified
Journal Article
Closed access
PDF file
ALAlex Listigovers
Alex Listigovers
LHLiwei He
Liwei He
LRLidice Bernardo Reyes
Lidice Bernardo Reyes
CHCamille Houy
Camille Houy
LELuciano Ettorre
Luciano Ettorre
SZShaolong Zhu
Shaolong Zhu
ELISA requirements: a crosslinked toxoid presents immune epitopes. Antibodies are screened by hydrogen deuterium exchange. Antibodies targeting separated neutralizing epitopes support in vitro potency testing, replacing in vivo .

27 July 2021
Verified
Preprint
Open access
PDF file
SZShaolong Zhu
Shaolong Zhu
PLPeter Liuni
Peter Liuni
TCTricia Chen
Tricia Chen
CHCamille Houy
Camille Houy
DWDerek Wilson
Derek Wilson
AJAndrew James
Andrew James
Background: Epitope mapping is an increasingly important aspect of biotherapeutic and vaccine development. Recent advances in therapeutic antibody design and production has enabled candidate mAbs to be identified at a rapidly increasing rate resulting in a significant bottleneck in the characterization of ‘structural’ epitopes, that are challenging to determine using existing high throughput epitope mapping tools. Here, Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS) epitope screening workflow was introduced that is well suited for accelerated characterization of epitopes with a common antigen. Main methods and major results: The method is demonstrated on set of 6 candidate mAbs targeting Pertactin (PRN). Using this approach, five of the six epitopes was unambiguously determined using two HDX mixing timepoints in 24 hours total run time, corresponding to substantial decrease in the instrument time required to map a single epitope using conventional HDX workflows. Conclusion: An accelerated HDX-MS epitope screening workflow was developed. The two-timepoint ‘screening’ workflow mapped all six mAbs and generated high confidence epitopes for five of the six mAbs assayed. The substantial improvement in the rate of data collection can advance HDX-MS for higher throughput investigations supporting the ability to evaluate a broader number of mAb candidates at an earlier stage of vaccine development.